National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting
Published Date: 2/2/2026
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 2, 2026, that’s partly open to the public and partly closed to protect private info about grant applications. Researchers and the public can join the open session online or in person, while the closed session will review important funding decisions. This meeting helps decide who gets money to study arthritis and related diseases, shaping future research and treatments.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Public Open Session and Videocast
You can attend the open part of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council meeting on June 2, 2026, from 9:30 a.m. to 2:00 p.m. in person at NIH Building 31 (31 Center Drive, Bethesda, MD 20892) or watch the videocast at https://videocast.nih.gov/. Registration is not required for the open portion.
Closed Session to Review Grant Applications
On June 2, 2026, from 2:15 p.m. to 4:30 p.m., the council will meet in closed session to review and evaluate grant applications; discussions may disclose confidential trade secrets, patentable material, or personal information and will be closed to protect that information. This closed review is part of deciding who receives research funding for arthritis and related diseases.
On‑site Security and Visitor ID Procedures
If you come to the NIH campus for the meeting, NIH security procedures require visitors to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit; all visitor vehicles will be inspected before being allowed on campus.
Reasonable Accommodations Available
If you need special assistance to attend the open session (for example, sign language interpretation), you should notify the Contact Person in advance so NIH can provide reasonable accommodations for the June 2, 2026 meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2026-01942, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Amended Notice of Meeting
Heads up! The Eunice Kennedy Shriver National Institute of Child Health and Human Development is extending its big May 2026 meeting from one day to two days. This change affects anyone interested in medical rehab research and means more time for important discussions, all happening in Bethesda and open to the public.
Next: 2026-01944, Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.